ArticleInternational journal of nanomedicine2026
Bioengineered Exosome-Magnetic Nanoplatform for Precision Therapy of Hepatocellular Carcinoma
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hepatocellular carcinoma (HCC) continues to pose a significant threat to global health, contributing substantially to worldwide cancer-related mortality, particularly in high-incidence regions such as Asia, where current treatment strategies are often limited by poor drug delivery efficiency, systemic toxicity, and drug resistance. Methods: To address these critical challenges, we developed an innovative dual-targeted nanoplatform (Exo-SPIONs-SRF/CGA) that synergistically combines the natural tumour-homing capability of HCC-derived exosomes with the magnetic guidance of superparamagnetic iron oxide nanoparticles (SPIONs) for precision drug targeting. This nanoplatform co-encapsulates SRF and CGA to improve the therapeutic index by enhancing desired responses and minimizing undesired side effects. Results: The exosome component provides inherent biological targeting to HCC cells. At the same time, the incorporated SPIONs enable external magnetic field-guided spatial control, collectively ensuring superior tumour accumulation compared to conventional delivery systems. Furthermore, the platform's tumour microenvironment-responsive release characteristics ensure localized drug activation, maximizing the therapeutic index through spatial and temporal control of drug availability. In vitro and in vivo evaluations demonstrated that this nanoplatform significantly enhances tumour suppression and drug retention while reducing systemic side effects compared to monotherapies or single-modality nanocarriers. Discussion: The Exo-SPIONs-SRF/CGA platform represents a promising strategy in HCC treatment, addressing fundamental limitations of current therapies by simultaneously overcoming biological barriers to drug delivery, enhancing therapeutic efficacy through synergistic drug combinations, and minimizing collateral damage to healthy tissues, thereby advancing the frontier of precision oncology toward more effective and safer HCC management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.